obesity-congress-diabetes-congress-2018-keynote

9 / 9

O c t o b e r 1 5 - 1 6 , 2 0 1 8 | T o k y o , J a p a n
Obesity Congress 2018, Diabetes Congress 2018 & Vaccines Congress 2018
Note:
Page 35
Biomedical Research | ISSN: 0976-1683| Volume 29
2nd WORLD OBESITY CONGRESS
2nd WORLD VACCINES AND IMMUNOLOGY CONGRESS
&
&
DIABETES AND ENDOCRINOLOGY
International Conference on
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Saida Marzanova, Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C5-012
THE PRESENT AND FUTURE OF
VACCINEAL PREVENTION OF ANIMAL
BRUCELLOSIS
T he effectiveness of corrective measures for brucellosis is largely deter-
mined by the quality of epidemiological surveillance and the effectiveness
of vaccine prevention. Used live vaccines do not fully protect against infection,
at the same time they pose a potential risk of Brucella infection in animals with
low immune resistance and post-vaccination complications and pose a danger
to livestock breeders and the population consuming untreated products from
vaccinated animals. Inactivated vaccines did not find practical application due
to insufficient efficacy and high reactogenicity. Considering that vaccination is
the basis for the prevention of Brucella infection, we conducted studies on the
selection of strains, developed and experimentally tested a split conjugated
biosafe vaccine based on immunogenically active subcellular and soluble pep-
tides of three Brucella strains: B.melitensis and two strains of Brucella bovis
biotype. To stimulate specific immunity, Brucella antigens were conjugated to
an immunoprotector. The immunoprotector was obtained from a culture of B
lymphocytes sensitized with Brucella antigens. Activity control was assessed
by immunostimulating of the mechanisms of cellular and humoral immunity
and immunogenic activity of the vaccine in guinea pigs. The immunogenic ac-
tivity of the declared vaccine was studied on guinea pigs weighing 300-400 g,
which were subcutaneously injected into the groin area with test specimens of
vaccines at a dose of 0.5 cm3. After four weeks vaccinated guinea pigs were
infected with a virulent culture of B. bovis 10 in an infectious dose (ID). At the
same time, non-vaccinated (control) guinea pigs were infected. 30 days after
infection, guinea pigs were killed and bacteriological seeding of lymph nodes
and organs on Brucella agar and Brucella broth was performed. Seeding was
sterile in 100% of vaccinated guinea pigs. In seeding from control unvaccinated
guinea pigs in 100% of cases, a culture of Brucella of the infecting strain was
isolated. As, a result, immunization of the split-conjugated brucellosis vaccine
activates the cellular and humoral immune response, enhancing the induction
of specific antibodies. Advantages of a split-conjugated vaccine: biosafety,
protection of immunized animals from infection with brucella during experi-
mental infection, reliably exceeds the specific efficiency of live anti-brucella
vaccines from strains B. abortus 19 and B. melitensis Rev-1.
Biography
Saida Marzanova has completed her PhD at the age
of 25 years from Moscow State Academy of Veteri-
nary Medicine and Biotechnology-MVA K. I. Skryabin,
Russia. She is the Associate Professor of Moscow
State Academy of Veterinary Medicine and Biotech-
nology-MVA K. I. Skryabin, Russia. She has over 50
publications that have been cited over 25 times, and
her publication H-index is 3 and has been serving as
an editorial board member of reputed Journal “Veter-
inary Medicine”.
Saida Marzanova
Devrishov D and Devrishov A
Moscow State Academy of Veterinary Medicine
and Biotechnology-MVA K. I. Skryabin, Russia